Tuberculosis treatment and drug regimens

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 5, 2015, Pages

  Sotgiu, Giovanni ^a   Centis, Rosella ^b   D’Ambrosio, Lia ^b   Battista Migliori, Giovanni ^b  

^a UNIVERSITY OF SASSARI   (Italy)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; DELAMANID; TUBERCULOSTATIC AGENT; NITROIMIDAZOLE DERIVATIVE; OPC-67683; OXAZOLE DERIVATIVE; QUINOLINE DERIVATIVE;

AIRBORNE INFECTION; ARTICLE; CHINA; DRUG COST; DRUG EFFICACY; DRUG RESISTANT TUBERCULOSIS; HEALTH CARE POLICY; HUMAN; INDIA; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT COMPLIANCE; PREVALENCE; USSR; DRUG EFFECTS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CHINA; DIARYLQUINOLINES; HUMANS; INDIA; MYCOBACTERIUM TUBERCULOSIS; NITROIMIDAZOLES; OXAZOLES; TUBERCULOSIS, MULTIDRUG-RESISTANT; USSR;

EID: 84930508201     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a017822     Document Type: Article

References (53)

1. Alffenaar JW, van Altena R, Harmelink IM, Filguera P, Molenaar E, Wessels AM, van Soolingen D, Kosterink JG, Uges DR, van der Werf TS. 2010. Comparison of the pharmacokinetics of two dosage regimens of linezolid in multidrug-resistant and extensively drug-resistant tuber- culosis patients. Clin Pharmacokinet 49: 559-565
2. Arentz M, Pavlinac P, Kimerling ME, Horne DJ, Falzon D, Schunemann HJ, Royce S, Dheda K, Walson JL, ART study group. 2012. Use of anti-retroviral therapy in tu- berculosis patients on second-line anti-TB regimens: A systematic review. PLoS ONE 7: e47370
3. Barry VC. 1964. Development of the chemotherapeutic agent for tuberculosis. In Chemotherapy of tuberculosis (ed. Barry VC). Butterworths, London
4. Crofton J. 1960. Tuberculosis undefeated. Br Med J 2: 679-687
5. Crofton J. 1969. Some principles in the chemotherapy of bacterial infections. Br Med J 2: 137-141
6. Crofton J. 2006. The MRC randomized trial of streptomycin and its legacy: A view from the clinical front line. J R Soc Med 99: 531-534
7. Daniel TM. 2006. The history of tuberculosis. Respir Med 100: 1862-1870
8. Dawson JJY, Devadatta S, Fox W, Radhakrishna S, Rama- krishnan CV, Somasundaram PR, Stott H, Tripathy SP, Velu S. 1966. A 5-year study of patients with pulmonary tuberculosis in a concurrent comparison of home and sanatorium treatment for one year with isoniazid plus PAS. Bull World Health Organ 34: 533-551
9. De Lorenzo S, Alffenaar JW, Sotgiu G, Centis R, D’Ambrosio L, Tiberi S, Bolhuis MS, van Altena R, Viggiani P, Piana A, et al. 2013. Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. Eur Respir J 41: 1386-1392
10. Dheda K, Migliori GB. 2012. The global rise of extensively drug-resistant tuberculosis: Is the time to bring back san- atoria now overdue? Lancet 379: 773-775
11. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Church-yard G, et al. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360: 2397-2405
12. Diacon AH, Dawson R, Hanekom M, Narunsky K, Venter A, Hittel N, Geiter LJ, Wells CD, Paccaly AJ, Donald PR. 2011. Early bactericidal activity of delamanid (OPC- 67683) in smear-positive pulmonary tuberculosis pa- tients. Int J Tuberc Lung Dis 15: 949-954
13. Diacon AH, Dawson R, von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, van Niekerk C, Everitt D, Winter H, Becker P, et al. 2012a. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: A randomised trial. Lancet 380: 986-993
14. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, et al. 2012b. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: Long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56: 3271-3276
15. Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, et al. 2012c. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob Agents Chemother 56: 3027-3031
16. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie A, Erondu N, Gins-berg AM, Egizi E, et al. 2013. Randomized dose-rang- ing study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum micros- copy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 57: 2199-2203
17. East African/British Medical Research Council. 1974. Con- trolled clinical treatment of short course (6 months) regime of chemotherapy for treatment of pulmonary tu-berculosis. Third report. Lancet 2: 237-248
18. Falzon D, Jaramillo E, Schunemann HJ, Arentz M, Bauer M, Bayona J, Blanc L, Caminero JA, Daley CL, Duncombe C, et al. 2011. WHO guidelines for the programmatic man- agement of drug-resistant tuberculosis: 2011 update. Eur Respir J 38: 516-528
19. Forgacs P, Wengenack NL, Hall L, Zimmerman SK, Silver- man ML, Roberts GD. 2009. Tuberculosis and trimetho-prim-sulfamethoxazole. Antimicrob Agents Chemother 53: 4789-4793
20. Fox W, Sutherland I, Daniels M. 1954. A five-year assess- ment of patients in a controlled trial of streptomycin in pulmonary tuberculosis: Report to the Tuberculosis Chemotherapy Trials Committee of the Medical Research Council. QJM 91: 347-366
21. Fox W, Ellard GA, Mitchison DA. 1999. Studies on the treat- ment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946 - 1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3: S231-S279
22. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, Awad M, Park SK, Shim TS, et al. 2012. Delamanid for multi- drug-resistant pulmonary tuberculosis. N Engl J Med 366: 2151-2160
23. Goldsworthy PD, McFarlane AC. 2002. Howard Florey, Al- exander Fleming and the fairy tale of penicillin. Med J Aust 176: 176-178
24. Grosset JH, Singer TG, Bishai WR. 2012. New drugs for the treatment of tuberculosis: Hope and reality. Int J Tuberc Lung Dis 16: 1005-1014
25. Hinshaw HC, Feldman WH. 1945. Streptomycin in the treatment of clinical tuberculosis; a preliminary report. Proc Staff Meet Mayo Clin 20: 313-318
26. Huang TS, Kunin CM, Yan BS, Chen YS, Lee SS, Syu W Jr. 2012. Susceptibility of Mycobacterium tuberculosis to sul-famethoxazole, trimethoprim and their combination over a 12 year period in Taiwan. J Antimicrob Chemother 67: 633-637
27. Koh WJ, Kang YR, Jeon K, Kwon OJ, Lyu J, Kim WS, Shim TS. 2012. Daily 300 mg dose of linezolid for multidrug-resistant and extensively drug-resistant tuberculosis: Updated analysis of 51 patients. J Antimicrob Chemother 67: 1503-1507
28. Mahajan R. 2013. Bedaquiline: First FDA-approved tuber- culosis drug in 40 years. Int J Appl Basic Med Res 3: 1-2
29. Migliori GB, Sotgiu G. 2012. Treatment of tuberculosis: Have we turned the corner? Lancet 380: 955–957
30. Migliori GB, Eker B, Richardson MD, Sotgiu G, Zellweger JP, Skrahina A, Ortmann J, Girardi E, Hoffmann H, Besozzi G, et al. 2009. A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug- resistant tuberculosis. Eur Respir J 34: 387-393
31. Migliori GB, Sotgiu G, Centis R, Grzemska M, Falzon D, Getahun H, Raviglione MC. 2011. Antituberculosis therapy and current global guidelines. In Current & emerging diagnostics, therapeutics & vaccines for tubercu- losis (ed. Kaufmann SHE), pp. 42-63. Future Medicine, London
32. Pontali E, Matteelli A, Migliori GB. 2013. Drug-resistant tuberculosis. Curr Opin Pulm Med 19: 266-272
33. Rosenblatt MB. 1973. Pulmonary tuberculosis: Evolution of modern therapy. Bull NY Acad Med 49: 163-196
34. Sakula A. 1983. Carlo Forlanini, inventor of artificial pneu-mothorax for treatment of pulmonary tuberculosis. Tho-rax 38: 326-332
35. Schatz A, Bugie E, Waksman SA. 1944. Streptomycin, a sub- stance exhibiting antibiotic activity against Gram-posi-tive and Gram-negative bacteria. ProcSoc Exp Biol Med 55: 66-69
36. Shaw KJ, Barbachyn MR. 2011. The oxazolidinones: Past, present, and future. Ann N Y Acad Sci 1241: 48-70
37. Sensi P. 1983. History of the development of rifampicin. Rev Infect Dis 5: 402-406
38. Skripconoka V, Danilovits M, Pehme L, Tomson T, Skenders G, Kummik T, Cirule A, Leimane V, Kurve A, Levina K, et al. 2013. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41: 1393-1400
39. Sotgiu G, Lange C, Richardson MD, Matteelli A, Centis R, Eker B, Guenther G, Spanevello A, Migliori GB; TBNET. 2009. Comment on: Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. J Antimicrob Chemother 64: 879-883
40. Sotgiu G, Centis R, D’Ambrosio L, Alffenaar JW, Anger HA, Caminero JA, Castiglia P, De Lorenzo S, Ferrara G, Koh WJ, et al. 2012. Efficacy, safety and tolerability of line- zolid containing regimens in treating MDR-TB and XDR-TB: Systematic review and meta-analysis. Eur Respir J 40: 1430-1442
41. Sotgiu G, Centis R, D’Ambrosio L, Migliori GB. 2013. Med- ical treatment of pulmonary tuberculosis. Eur Respir So- ciety Monograph 61: 11-19
42. Srivastava S, Peloquin CA, Sotgiu G, Migliori GB. 2013. Therapeutic drug management: Is it the future of multi-drug-resistant tuberculosis treatment? Eur Respir J 42: 1449-1453
43. Tuberculosis Coalition for Technical Assistance. Internation- al Standards for Tuberculosis Care (ISTC), 2nd ed. 2009. Tuberculosis Coalition for Technical Assistance, The Hague
44. Vilchèze C, Jacobs WR Jr. 2012. The combination of sulfa- methoxazole, trimethoprim, and isoniazid or rifampin is bactericidal and prevents the emergence of drug resis- tance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 56: 5142-5148
45. Wallis RS, Jakubiec W, Mitton-Fry M, Ladutko L, Campbell S, Paige D, Silvia A, Miller PF. 2012. Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide. PLoS ONE 7: e30479
46. Wassersug JD. 1946. Pulmonary tuberculosis. N Engl J Med 235: 220-229
47. Willyard C. 2012. Race heats up for first-to-market drugs for resistant tuberculosis. Nat Med 18: 1157
48. World Health Organization. 2004. Toman’s tuberculosis: Case detection, treatment and monitoring, second edition. WHO, Geneva
49. World Health Organization. 2008. Guidelines for the pro- grammatic management of drug-resistant tuberculosis. Emergency update 2008. WHO/HTM/TB/2008.402. WHO, Geneva
50. World Health Organization. 2010. The treatment of tuber- culosis guidelines. Document WHO/HTM/TB/2009.420. WHO, Geneva
51. World Health Organization. 2011a. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Policy statement. WHO/HTM/TB/2011.4. WHO, Geneva
52. World Health Organization. 2011b. Guidelines for the pro- grammatic management of drug-resistant tuberculosis, 2011 update. WHO/HTM/TB/2011.6. WHO, Geneva. World Health Organization. 2013a. Global tuberculosis re-port 2013. WHO/HTM/TB/2013.11. WHO, Geneva
53. World Health Organization. 2013b. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis: In- terim policy guidance. WHO, Geneva